News archive
308 results
-
The composition of Fimea’s patient advisory board for the term 2020–2021 has been confirmed
-
Clinical trial materials can be sent electronically for the duration of the post office strike
-
The health technology guidance and supervision tasks will be moved from Valvira to Fimea
-
The Homeopathic Medicinal Products Working Group convened for its meeting during Finland’s EU presidency
-
Guidelines for marketing authorisation holders for notifying nitrosamine evaluation outcomes
-
Fimea started its operations 10 years ago
-
Joint session of CHMP and PRAC in Helsinki
-
Clinical drug trials to be processed electronically
-
European medicines regulatory network working on a common strategy
-
Meeting on veterinary medicinal products discussed issues arising from the new Regulation
-
Scheduled downtime of Fimea email communication 26–27 October
-
The marketing authorisation holders to review their medicinal products for the existence of nitrosamine impurities
-
To marketing authorisation holders: The process for notifying shortages will change gradually starting from 1 October 2019
-
For marketing authorisation holders: the naming of certain liposomal medicinal products must be further specified by 30 September
-
Meds75+ database shortlisted as the medication safety influencer of the year
-
EU pharmaceutical industry operators seek closer cooperation
-
The EU and the USA reach a milestone on the mutual recognition of GMP inspections of pharmaceutical manufacturers
-
Fimea to host a number of pharmaceutical meetings during Finland's Presidency
-
Fimea issued Fysioline Oy with a marketing ban decision concerning the use of starter packs of the Trampalgin medicinal product in marketing
-
Cannabidiol (CBD) is controlled as a medicine in Finland
Showing 241 - 260 / 308
